Evidence map›Paper›PMID 29123013›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2018

Jeremie Calais, Johannes Czernin, Minsong Cao, Amar U Kishan, John V Hegde, Narek Shaverdian, Kiri Sandler, Fang-I Chu, Chris R King, Michael L Steinberg and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Prospective, Multisite, International Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Trial
  13. European journal of nuclear medicine and molecular imaging · 2019
    Trial
  14. Potential Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018
    Trial
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Review

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Jeremie CalaisAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California jcalais@mednet.ucla.edu.
Johannes CzerninAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Minsong CaoDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Amar U KishanDepartment of Radiation Oncology, UCLA, Los Angeles, California.
John V HegdeDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Narek ShaverdianDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Kiri SandlerDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Fang-I ChuDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Chris R KingDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Michael L SteinbergDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Isabel RauscherDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Nina-Sophie Schmidt-HegemannDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Thorsten PoeppelDepartment of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany.
Philipp HetkampDepartment of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany.
Francesco CeciAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Ken HerrmannAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Wolfgang P FendlerAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Matthias EiberAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Nicholas G NickolsDepartment of Radiation Oncology, UCLA, Los Angeles, California.

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

Target volume delineations for prostate cancer (PCa) salvage radiotherapy (SRT) after radical prostatectomy are usually drawn in the absence of visibly recurrent disease.

Indexed as

OligopeptidesPositron Emission Tomography Computed TomographyProstatectomyRadiotherapy Planning, Computer-AssistedSalvage TherapyAdultAgedAged, 80 and overEdetic AcidGallium IsotopesGallium RadioisotopesHumansImage Processing, Computer-AssistedMaleMiddle AgedProstate-Specific AntigenEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptidesProstate-Specific AntigenPET/CTprostate cancerPSMArecurrencesalvage radiotherapy

Identifiers

PMID29123013
PMCPMC5807533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.